Anna Maria Frezza
Overview
Explore the profile of Anna Maria Frezza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
927
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sigalotti L, Frezza A, Sbaraglia M, Del Savio E, Baldazzi D, Valenti B, et al.
Mod Pathol
. 2024 Nov;
38(1):100647.
PMID: 39491746
Epithelioid sarcoma (ES) is a rare tumor hallmarked by the loss of INI1/SMARCB1 expression. Apart from this alteration, little is known about the biology of ES. Despite recent advances in...
2.
Frezza A, Leonard H, Aggerholm-Pedersen N, Badalamenti G, Baili P, Baldi G, et al.
PLoS One
. 2024 Aug;
19(8):e0308387.
PMID: 39133752
Introduction: Epithelioid hemangioendothelioma (EHE) is an ultra-rare sarcoma, marked by distinctive molecular and pathological features and with a variable clinical behavior. Its natural history is still partially understood, reliable prognostic...
3.
Palassini E, Baldi G, Sulfaro S, Barisella M, Bianchi G, Campanacci D, et al.
Cancer Treat Rev
. 2024 Apr;
126:102722.
PMID: 38604052
Angiosarcoma (AS) represents a rare and aggressive vascular sarcoma, posing distinct challenges in clinical management compared to other sarcomas. While the current European Society of Medical Oncology (ESMO) clinical practice...
4.
Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study
Stacchiotti S, Baldi G, Frezza A, Morosi C, Greco F, Collini P, et al.
Eur J Cancer
. 2023 Nov;
195:113391.
PMID: 37918286
Background: To investigate the activity of regorafenib in advanced solitary fibrous tumour (SFT). Methods: An Italian monocentric investigator-initiated exploratory single-arm Phase II trial was conducted of regorafenib in adult patients...
5.
Grunewald T, Postel-Vinay S, Nakayama R, Berlow N, Bolzicco A, Cerullo V, et al.
Clin Cancer Res
. 2023 Nov;
30(6):1079-1092.
PMID: 37916971
Epithelioid sarcoma (EpS) is an ultra-rare malignant soft-tissue cancer mostly affecting adolescents and young adults. EpS often exhibits an unfavorable clinical course with fatal outcome in ∼50% of cases despite...
6.
Danieli M, Barretta F, Radaelli S, Fiore M, Sangalli C, Barisella M, et al.
Cancer
. 2023 Jul;
129(21):3417-3429.
PMID: 37452607
Background: To explore the correlation between pathological and radiological response to preoperative treatments and outcome in surgically treated patients with myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS). Methods: All consecutive...
7.
Zuco V, Pasquali S, Tortoreto M, Percio S, Doldi V, Barisella M, et al.
Dis Model Mech
. 2023 May;
16(6).
PMID: 37158111
This study exploited a novel patient-derived xenograft (PDX) of desmoplastic small round cell tumor (DSRCT), which reproduces histomorphological and molecular characteristics of the clinical tumor, to assess the activity of...
8.
Giani C, Radaelli S, Miceli R, Gandola L, Sangalli C, Frezza A, et al.
Cancer Med
. 2023 Mar;
12(9):10694-10703.
PMID: 36951537
Objective: To report on a retrospective study of primary DSRCT aiming at characterizing long-term survivors (LTS). Methods: All consecutive patients treated at our institution for a primary DSRCT between 2000...
9.
Stacchiotti S, Frezza A, Demetri G, Blay J, Bajpai J, Baldi G, et al.
Cancer Treat Rev
. 2022 Aug;
110:102455.
PMID: 36031697
Background: In ultra-rare sarcomas (URS) the conduction of prospective, randomized trials is challenging. Data from retrospective observational studies (ROS) may represent the best evidence available. ROS implicit limitations led to...
10.
Nasca V, Frezza A, Morosi C, Buonomenna C, Parafioriti A, Zappala G, et al.
Front Oncol
. 2022 Aug;
12:953149.
PMID: 35928864
Giant cell tumor of the bone (GCTB) is a locally aggressive neoplasm where surgery is often curative. However, it can rarely give rise to distant metastases. Currently, the only available...